Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter

Physiological Genomics

Volumn 2002, Issue 7, 2002, Pages 187-200

  Lee, Tae Ho ^a   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Gene regulation; Vitamin D receptor; Wilms' tumor

Indexed keywords

MURINAE;

CALCITRIOL RECEPTOR; WT1 PROTEIN;

ALLELE; ARTICLE; BINDING COMPETITION; BINDING SITE; CELL LINE; CYTOLOGY; DENYS DRASH SYNDROME; GC RICH SEQUENCE; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; HUMAN; KIDNEY; METABOLISM; NEPHROBLASTOMA; PHYSIOLOGY; PROMOTER REGION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

ALLELES; BINDING SITES; BINDING, COMPETITIVE; CELL LINE; DENYS-DRASH SYNDROME; GC RICH SEQUENCE; GENE EXPRESSION PROFILING; HUMANS; KIDNEY; MUTAGENESIS, SITE-DIRECTED; PROMOTER REGIONS (GENETICS); RECEPTORS, CALCITRIOL; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRANSFECTION; WILMS TUMOR; WT1 PROTEINS;

EID: 0346740255     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Brown AJ, Dusso A, and Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 277: F157-F175, 1999.
2. Bruening W, Moffett P, Chia S, Heinrich G, and Pelletier J. Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product. FEBS Lett 393: 41-47, 1996.
3. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C, and Housman DE. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520, 1990.
4. 3. Biochem J 316: 361-371, 1996.
5. Chun LY, Pirro AE, Amling M, Delling G, Baron R, Bronson R, and Demay MB. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94: 9831-9835, 1997.
6. Coppes MJ, Liefers GJ, Paul P, Yeger H, and Williams BRG. Homozygous somatic Wt1 point mutations in sporadic unilateral Wilms tumor. Proc Natl Acad Sci USA 90: 1416-1419, 1993.
7. Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI, and Hastie ND. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 12: 3217-3225, 1998.
8. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, and Bruns GAP. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343: 774-778, 1990.
9. Goodyer P, Dehbi M, Torban E, Bruening W, and Pelletier P. Repression of the retinoic acid receptor-α gene by the Wilms' tumor suppressor gene product, wt1. Oncogene 10: 1125-1129, 1995.
10. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, and Shi Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16: 6945-6956, 1996.
11. Johnstone RW, Wang J, Tommerup N, Vissing H, Roberts T, and Shi Y. Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1. J Biol Chem 273: 10880-10887, 1998.
12. Kim J, Prawitt D, Bardeesy N, Torban E, Vicaner C, Goodyer P, Zabel B, and Pelletier J. The Wilms tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol 19: 2289-2299, 1999.
13. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, and Jaenisch R. WT-1 is required for early kidney development. Cell 74: 679-691, 1993.
14. Laity JH, Dyson HJ, and Wright PE. Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein. Proc Natl Acad Sci USA 97: 11932-11935, 2000.
15. Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heyningen V, and Hastie N. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 81: 391-401, 1995.
16. Lee SB and Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 264: 74-99, 2001.
17. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, and Haber DA. The Wilms suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98: 663-673, 1999.
18. Little MH, Prosser J, Condie A, Smith PJ, van Heyningen V, and Hastie ND. Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA 89: 4791-4795, 1992.
19. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10: 142-153, 1996.
20. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, and Rauscher FJ III. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 253: 1550-1553, 1991.
21. Maheswaran S, Englert C, Zheng G, Lee SB, Wong J, Harkin DP, Bean J, Ezzell R, Garvin AJ, McCluskey RT, DeCaprio JA, and Haber DA. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev 12: 1108-1120, 1998.
22. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ, Hill DE, and Haber DA. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 90: 5100-5104, 1993.
23. Matsunaga E. Genetics of Wilms' tumor. Hum Genet 57: 231-246, 1981.
24. Maurer U, Jehan F, Englert C, Hübinger G, Weidmann E, DeLucas HF, and Bergmann L. The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor (VDR). J Biol Chem 276: 3727-3732, 2001.
25. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, and Baldwin AS. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 18: 3990-4003, 1999.
26. Miller RW, Fraumeni JF Jr, and Manning MD. Association of Wilms' tumor with aniridia, hemihypertrophy and other congenital malformation. N Engl J Med 270: 922-927, 1964.
27. Miyamoto KI, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, Inoue Y, Morita K, Takeda E, and Pike JW. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 11: 1165-1179, 1997.
28. Moffett P, Bruening W, Nakagama H, Bardeesy N, Housman D, Housman DE, and Pelletier J. Antagonism of WT1 activity by protein self-association. Proc Natl Acad Sci USA 92: 11105-11109, 1995.
29. Nakagama H, Heinrich G, Pelletier J, and Housman D. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol 15: 1489-1498, 1995.
30. Park S, Bernard A, Bove K, Sens DA, Hazen-Martin DJ, Julian Garvin A, and Haber DA. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nat Genet 5: 363-367, 1993.
31. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L, Fine RN, Silverman BL, Haber DA, and Housman D. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67: 437-447, 1991.
32. Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, and Housman DE. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 353: 431-434, 1991.
33. Rackley RR, Flenniken AM, Kuriyan NP, Kessler PM, Stoler MH, and Williams BRG. Expression of the Wilms' tumor suppressor gene wt1 during mouse embryogenesis. Cell Growth Differ 4: 1023-1031, 1993.
34. Rauscher FJ III, Morris JF, Tournay OE, Cook D, M, and Curran T. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 250: 1259-1262, 1990.
35. Reddy JC and Licht JD. The WT1 Wilms' tumor suppressor gene: how much do we really know? Biochim Biophys Acta 1287: 1-28, 1996.
36. Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, and Licht JD. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 270: 10878-10884, 1995.
37. Sambrook J, Fritsch EF, and Maniatis T. Molecular Cloning: a Laboratory Manual (2nd ed.). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
38. Silberstein GB and Daniel CW. Reversible inhibition of mammary gland growth by transforming growth factor-beta. Science 237: 291-293, 1987.
39. Stanhope-Baker P and Williams BRG. Identification of connective tissue growth factor as a target of WT1 transcriptional regulation. J Biol Chem 275: 38139-38150, 2000.
40. Varanasi R, Bardeesy N, Ghahremani M, Petruzzi MJ, Nowak N, Adam MA, Grundy P, Shows T, and Pelletier J. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci USA 91: 3554-3558, 1994.
41. Wagner KD, Wagner N, Sukhatme VP, and Scholz H. Activation of vitamin D receptor by the Wilms' tumor gene product mediates apoptosis of renal cells. J Am Soc Nephrol 12: 1188-1196, 2001.
42. Wang ZY, Qiu QQ, Huang J, Gurrieri M, and Deuel TF. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene 10: 415-422, 1995.
43. Wang ZY, Qui QQ, and Deuel TF. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J Biol Chem 268: 9172-9175, 1993.
44. Wang ZY, Qui QQ, Enger KT, and Deuel TF. A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. Proc Natl Acad Sci USA 90: 8896-8900, 1993.
45. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami A, Matsumoto T, and Kato M. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16: 391-396, 1997.